Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Hinova Pharmaceuticals Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 3 distinct examiners across 2 distinct art units. The busiest examiner, AGGARWAL, SAHIL CHANDER, is responsible for 1 pending office action, indicating that the workload is spread among the examiners. The fact that 3 pending office actions are distributed across 2 distinct art units suggests some level of technical overlap in the company's pharmaceutical filings.
While there are 3 distinct examiners, some likely work within the same art unit. For practitioners, this means that while they must navigate 3 distinct examiner personalities, they may encounter similar art unit policies for at least some of the actions. This profile shows a focused but slightly diversified approach within the Biotechnology & Pharmaceuticals sector. The 3 pending office actions require a strategy that addresses the specific requirements of the 2 distinct art units. Since the busiest examiner, AGGARWAL, SAHIL CHANDER, only handles 1 pending office action, practitioners must engage with all assigned examiners to advance the portfolio. This distribution allows for some comparison of examiner behavior within the same art unit for the pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| FOWLER, ALAN JEROME | 1 | 100.0% | +0.0% |
| ABBAS, ABDULRAHMAN MUSTAFA | 1 | 51.6% | +29.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18881773 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | AGGARWAL, SAHIL CHANDER | — |
| 18293289 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | FOWLER, ALAN JEROME | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17055862 | HC-1119 FORMULATION, PREPARATION METHOD AND USE THEREOF | ABBAS, ABDULRAHMAN MUSTAFA | 70d |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18881773 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | AGGARWAL, SAHIL CHANDER | — | §101§102§112 | Non-Final OA | — | Pending | Jan 07, 2025 |
| 18293289 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | FOWLER, ALAN JEROME | 1691 | §102§103§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
| 17055862 | HC-1119 FORMULATION, PREPARATION METHOD AND USE THEREOF | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103 | Final Rejection | 70d | Pending | Jun 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHinova Pharmaceuticals Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Sahil Chander Aggarwal has the most, with 1 of Hinova Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
